The draft updated guidance on assessing and preventing falls in older people and people aged 50 and over at higher risk opens ...

First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended ...

Demand for NHS Talking Therapies has reached an all-time high. The service received 1.82 million referrals in 2023/24. This is slightly higher than 2021/2022, and more than double the 884,000 received ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

A list of downloadable documents created during development.

Suggested remit: To appraise the clinical and cost effectiveness of iptacopan within its marketing authorisation for treating complement 3 (C3) glomerulopathy.

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Dear stakeholders, For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...